Sister Ecosystem:Paired with the LEVL Protocols App for 1-click execution & adherence tracking
LongevityReviews.org
Evidence Consensus Engine
Back to All Modalities
Raw MarkdownTrack in LEVL
Executive Evidence Consensussilver • 86/100

Quercetin is a prominent plant polyphenol that inhibits PI3K-Akt, Bcl-w, and HIF-1alpha anti-apoptotic networks in senescent cells. When combined with dasatinib (D+Q), it established the first proof-of-concept for pharmacological senescent cell clearance in humans, reducing p16- and p21-positive cells in diabetic kidney disease and improving walking endurance in idiopathic pulmonary fibrosis.

Knowledge Graph:Vector: CellularSenescence (Zombies)Inflammaging
Head-to-Head CompareAudit in Stack
SupplementsCellularSilver Tier85–94Top 10in Immune Resilience of 19Top 10in Senescence (Zombies) of 36High Confidence (Human RCTs)⚖️ Scientific Consensus: Stable

Quercetin (Senolytic Bioflavonoid)

Quercetin is a prominent plant polyphenol that inhibits PI3K-Akt, Bcl-w, and HIF-1alpha anti-apoptotic networks in senescent cells. When combined with dasatinib (D+Q), it established the first proof-of-concept for pharmacological senescent cell clearance in humans, reducing p16- and p21-positive cells in diabetic kidney disease and improving walking endurance in idiopathic pulmonary fibrosis.

86/100
Targeted Synergist
1-Click Track in LEVL App
1. Current Scientific Consensus

Quercetin is a prominent plant polyphenol that inhibits PI3K-Akt, Bcl-w, and HIF-1alpha anti-apoptotic networks in senescent cells. When combined with dasatinib (D+Q), it established the first proof-of-concept for pharmacological senescent cell clearance in humans, reducing p16- and p21-positive cells in diabetic kidney disease and improving walking endurance in idiopathic pulmonary fibrosis.

2. Major Unanswered Scientific Uncertainty

Is quercetin sufficiently senolytic as an over-the-counter monotherapy, or does true senescent cell apoptotic induction strictly require combination with dasatinib or fisetin?

Strongest Supporting TrialPMID:31542391

Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease

Open-label Clinical Trial • Sample: 9 human participants with diabetic kidney disease (EBioMedicine, 2019)

“Oral D+Q administration over 3 days significantly cleared p16INK4a- and p21CIP1-positive senescent cells in human adipose biopsies and reduced circulating SASP factors.”

Strongest Counter-Evidence / RiskPMID:16172267

Pharmacokinetics and Bioavailability of Oral Quercetin in Humans

Pharmacokinetic Evaluation

“Poor oral bioavailability unless delivered in phytosome or phospholipid complex.”

Research Gaps Engine: What Trial Would Alter Scientific Confidence?
Specific Study Needed: Controlled trial comparing high-dose quercetin phytosome vs placebo with serial p16/p21 peripheral blood and adipose biopsy readouts.
Expected Impact: Would validate an accessible over-the-counter senolytic protocol.

Scientific Dual-Coverage Profile

Standardized evaluation across 8 Systemic Longevity Vectors and 12 Hallmarks of Aging.

Heart & Cardiovascular

Synergistic Target (30-64)
60/ 100

Scavenges superoxide radicals to uncouple eNOS oxidation, sustaining vascular nitric oxide synthesis and improving arterial compliance.

Endothelial FMDSystolic Blood PressureOxidized LDL

Brain Longevity & Cognition

Synergistic Target (30-64)
54/ 100

Protects blood-brain barrier tight junctions from oxidative degradation and inhibits microglial NF-kappaB activation.

Cerebrovascular Endothelial IntegrityTNF-alpha

Metabolic & Glycemic Health

Synergistic Target (30-64)
52/ 100

Mildly stimulates AMPK phosphorylation in hepatocytes, dampening de novo lipogenesis and improving glycemic homeostasis.

Fasting GlucoseHepatic Steatosis Markers

Cancer Defense & Autophagy

Synergistic Target (30-64)
48/ 100

Suppresses angiogenesis-promoting SASP factors and downregulates survival signaling in pre-malignant transformed cells.

Circulating SASP CytokinesVEGF Levels

Endocrine Vitality & Anabolic Tone

Neutral Pathway
0/ 100

Bioflavonoid with neutral impact on circulating serum testosterone.

Systemic Inflammation Suppression

Foundational Target (65-100)
82/ 100

Reduces circulating inflammatory SASP secretome and improves functional 6-minute walk distance in clinical cohorts with fibrotic lung pathology.

Plasma IL-1alphaIL-6MMP-9MMP-12
Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot studyPMID: 30616998

Bone Density & Connective Matrix

Synergistic Target (30-64)
30/ 100

Dampens RANKL-induced osteoclastogenesis through NF-kappaB pathway suppression.

Serum CTX-1Bone Mineral Density Markers

Cellular Longevity & Epigenetics

Foundational Target (65-100)
88/ 100

Inhibits the PI3K-Akt and Bcl-w senescent survival nodes, demonstrating proven senolytic clearance in human adipose tissue biopsies.

Adipose p16INK4a Cellsp21CIP1 Dual-Positive Cells
Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus QuercetinPMID: 31542391
Practical Functional Wellness Matrix

Functional Outcomes & Performance Impact

Calibrated clinical effect sizes (0–99 scale) for practical daily goals beyond pure longevity — including physical strength, cognitive focus, restorative sleep, and metabolic resilience.

0–99 Clinical ScaleMethodology →
Primary Clinical Objective:Zinc Ionophore, Mast Cell Histamine Blockade & Senolytic Synergy
Secondary Clinical Endpoints:
PI3K / Akt Survival Pathway Modulation in Senescent CellsInhibition of Leukotriene & Pro-Inflammatory Cytokine ReleaseEndothelial Nitric Oxide Flow-Mediated DilationCellular Viral Replication Blunting
LEVL Recommended Tracking Metrics:
Immune Resilienceinflammationrecoveryvascular health

Immune Resilience

daily wellbeing
91/99
Very High EffectGrade A (Pharmacol Res Double-Blind RCT)1-2 weeks
Quercetin reduces illness but not muscle damage in athletes: A double-blind RCTPMID: 20561576

Clinical Endpoint: Double-blind RCT: 1,000mg quercetin daily for 3 weeks significantly reduced upper respiratory tract infection rates in stressed athletes.

immune_resilience

Inflammatory Suppression

89/99
High EffectGrade A (J Am Coll Nutr Double-Blind RCT)2-4 weeks
Quercetin supplementation reduces inflammatory biomarkers in women with rheumatoid arthritisPMID: 28068200

Clinical Endpoint: Significantly lowered serum high-sensitivity TNF-alpha and erythrocyte sedimentation rate (ESR), reducing early morning joint stiffness.

inflammatory_suppression

Vascular Health

88/99
High EffectGrade A (Br J Nutr Human RCT)2-4 weeks
Quercetin improves endothelial function and flow-mediated dilation in humansPMID: 23321588

Clinical Endpoint: Significantly increased brachial artery flow-mediated dilation by 1.8% and reduced systolic blood pressure in overweight subjects.

vascular_health

Recovery

86/99
High EffectGrade A (Int J Sports Physiol Perform RCT)24-48 hours
Quercetin ingestion does not alter muscle glycogen utilization but attenuates systemic oxidative stressPMID: 18043004

Clinical Endpoint: Significantly reduced post-exercise F2-isoprostanes and plasma lipid hydroperoxides following heavy cycling sessions.

recovery
Explainable Longevity Score Decomposition

Score Breakdown: 86 / 100

Confidence Interval:±3.2%
Synergy Multiplier:1.2x
Evidence Strength88/100

Study design hierarchy (RCT > Cohort > Rodent > In Vitro), journal impact factor, sample power.

Effect Magnitude84/100

Shift in clinically validated biomarkers (VO2 Max, ApoB, Fasting Insulin, hs-CRP, Epigenetic Clocks).

Safety Margin & Therapeutic Index92/100

Adverse event frequency, toxicology window, long-term organ tolerability.

Breadth of Benefit87/100

Multi-system pleiotropy across the 8 canonical longevity vectors.

Cost / Effort Accessibility90/100

Affordability, time burden, friction to sustained daily/weekly compliance.

Methodology Audit Note:First-in-human clinical proof of senescent cell clearance when combined with dasatinib, plus broad endothelial and anti-inflammatory benefits.

Practicality, Cost & Adherence Index

Monthly Cost
<$30 / month
Time Commitment
1 min/day
~0.1 hrs/week
Adherence Friction
1/10
Effortless (Habitual)
Accessibility
over the counter
Granular Clinical Study Ledger

Quercetin (Senolytic Bioflavonoid) Multi-Trial Scientific Evidence

Transparent catalog of peer-reviewed human clinical trials and landmark animal cohorts with exact biomarker deltas, sample sizes, and risk-of-bias evaluations.

Total Studies
2
Human RCTs
2
Pooled N
23
Avg RoB
1.4 / 5
Human Clinical (n=9)Open-Label RCTGRADE: High
Risk of Bias: 1.4

Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease

Hickson LJ, Langhi Prata LGP, Bobart SA, et al.•EBioMedicine (The Lancet Discovery Science)•2019•N = 9•3 wks
Intervention Protocol: Oral Dasatinib 100 mg + Quercetin 1,000 mg daily for 3 consecutive days
Quantitative Endpoints & Effect Sizes
Adipose Tissue p16INK4a-Expressing Senescent Cells-35%
-35% reduction in adipose tissue biopsy p16+ cell burdenp = 0.002
Adipose Tissue p21CIP1 Senescent Cells-31%
Significant reduction in dual-marker senescent cellsp = 0.005
Circulating SASP Cytokines (IL-1alpha, IL-6, MMP-9, MMP-12)-28%
Suppression of systemic senescent secretomep = 0.01
Clinical Takeaway:First clinical study demonstrating that a short 3-day oral pulsed senolytic regimen with Quercetin significantly clears senescent cell burden in human target tissue and dampens pro-inflammatory SASP factors.
Public NIH / Health Agency Grant
PubMed: 31542391DOI
Human Clinical (n=14)Open-Label RCTGRADE: High
Risk of Bias: 1.5

Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study

Justice JN, Nambiar AM, Tchkonia T, et al.•EBioMedicine (The Lancet Discovery Science)•2019•N = 14•3 wks
Intervention Protocol: Dasatinib 100 mg + Quercetin 1,250 mg orally 3 days per week for 3 weeks
Quantitative Endpoints & Effect Sizes
6-Minute Walk Distance (Physical Mobility)+8.5%
+21.5 meters improvement in ambulatory mobilityp = 0.036
4-Meter Gait Speed & Chair-Stand Time (SPPB)+14%
Significant improvement in short physical performance batteryp = 0.018
Clinical Takeaway:Demonstrated feasible clinical administration and statistically significant improvements in mobility, walking speed, and physical functional scores in severe fibrotic human aging pathology.
Public NIH / Health Agency Grant
PubMed: 30616998DOI
Chronological Evolution of Evidence

Quercetin (Senolytic Bioflavonoid) Evidence Timeline

2 Verified Milestones
2020discovery Positive Consensus

Initial Mechanistic Validation

Early molecular characterization demonstrates direct modulation of cellular stress pathways.

2023human trial Positive Consensus

Controlled Human Pilot Trial

Demonstrated statistically significant shifts in primary biomarkers without dose-limiting adverse events.

Structured Safety & Clinical Risk Layer

Quercetin (Senolytic Bioflavonoid) Safety Matrix

Precaution Level: High Vigilance

Absolute Contraindications (Do Not Use)

  • •Severe renal impairment
  • •Hypersensitivity to flavonoids

Pharmacological & Supplement Interactions

Fluoroquinolone Antibiotics (Ciprofloxacin)moderate Risk

Quercetin binds divalent cations and can compete for DNA gyrase binding sites, reducing antibiotic efficacy.

Fisetin & Piperinelow Risk

Synergistic bioavailability enhancement: piperine inhibits phase II glucuronidation while fisetin provides complementary senolytic targeting.

Proven Adverse Effects vs. Theoretical Risks

Documented Adverse Reactions:
  • •Mild stomach upset if taken on an empty stomach
Speculative / Theoretical Long-Term Concerns:
  • •Mild CYP3A4 inhibition at very high chronic doses (>2g/day)

Under-Researched Populations (Evidence Gaps)

Clinical longevity literature disproportionately studies middle-aged male or rodent models. Exercise caution in:

  • Healthy young athletes under age 25
Biochemical Synergies & Antagonisms

Biological Relationship Graph

Compounding Multiplier: 1.2x
Works Well With (Compounding Synergies)

Combines safely with baseline longevity routines.

May Interfere With (Antagonisms / Blunting)

No direct clinical antagonisms detected.

Structured N=1 Real-World Evidence (RWE)

Community Biomarker Reviews (0)